Blood Cell Technologies LLC Profile last edited on: 9/8/2023
CAGE: 76LR5
UEI: HH9LT9M9B3N4
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
9 Shipyard Lane
Setauket, NY 11733
Setauket, NY 11733
| (631) 751-3467 |
| N/A |
| N/A |
Location: Single
Congr. District: 01
County: Suffolk
Congr. District: 01
County: Suffolk
Public Profile
Blood Cell Technologies LLC is usefully understood as an early-stage start-up: an R&D company focused on identifying and validating novel cellular and diagnostic technologies relevant to human blood disorders. Principals of the firm describe themselves as structured around identifying, validating, and commercializing novel drug targets and compounds that may (could) be being used to diagnose or treat blood cell disorders, enabling clinicians to enhance platelet production in humans by the first-in-class redox-inhibiting compounds
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 1 | NIH | $285,200 | |
| Project Title: Development of a new class of BLVRB-targeted redox therapeutics in breast cancer | ||||
| 2022 | 2 | NIH | $1,454,958 | |
| Project Title: Optimization of biliverdin IX? reductase redox inhibitors as novel reagents for enhancing platelet production | ||||
| 2020 | 1 | NIH | $272,302 | |
| Project Title: Detection Of Fetal Platelets In Maternal Blood Using Platelet Rna Biomarkers. | ||||
| 2017 | 1 | NIH | $243,104 | |
| Project Title: HLS-Detection of RNA biomarkers in individual platelets | ||||
| 2015 | 1 | NIH | $220,991 | |
| Project Title: Development of a Biliverdin IX Beta Reductase Redox Inhibitor for Enhanced Platelet Production | ||||
Key People / Management
Dmitri V Gnatenko
Marchenko
Natasha M Nesbitt -- Chief Scientific Officer
Marchenko
Natasha M Nesbitt -- Chief Scientific Officer
Company News
There are no news available.
